

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

ASMS 2019 ThP 513

Megumi Sakuma¹, Keisuke Shima², Shinji Funatsu², Koretsugu Ogata², Miyuki Morozumi¹, Satoshi Iwata¹ ¹ Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan,

PO-CON1849E

² Shimadzu Corporation, Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto, Japan

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

Introduction and Overview

Microbial identification techniques using matrix-assisted laser desorption/ionization mass spectrometers (MALDI-TOF MS) are becoming more common as the process of identification is faster and simpler than conventional methods. MALDI-TOF MS has already gained a position as an instrument for identification techniques. For further expansion, numerous efforts are being made to utilize MALDI instruments for microbial tests other than identification. Recently, invasive infections caused by group A streptococcus (GAS) are on the increase. Among these, the *emm*1 group A streptococci has high pathogenicity, and its invasive infection cases indicate a significantly high possibility of developing into a fulminant form (Fig. 1). It is said that both its case fatality rate and rate of complications are high. This article introduces an example of differentiating between the highly pathogenic *emm*1 type and other types using MALDI-TOF MS and the statistical analysis software eMSTAT Solution¹.



Fig. 1 emm types of GAS strains from invasive infections²



Fig. 2 Comparison of Mass Spectra of the Group A Streptococcus *emm*1 Type and the Other Types

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

Methods and Materials

Bacterial strains

Among the GAS strains derived from invasive infections, we used 10 strains each of *emm1*, *emm12*, *emm28* and *emm89*, which have a high isolation frequency, and conducted a search for markers that help to differentiate *emm* types. The above four *emm* types were cultured on a blood agar medium for 24 hours, Furthermore, we used 379 strains derived from pharyngitis and tonsillitis, including groups B, C, and G streptococci for blind tests.

MALDI-TOF MS

Instrument:	iD ^{plus} MALDI microbial identification platform (Shimadzu)
Tuning mode:	Linear positive
Matrix solution:	Sinapinic acid 10 mg/mL (50 % acetonitrile 1 % TFA)
Sample preparation:.	Bacterial cells were collected and suspended in 0.5 mL of 70%(v/v) ethanol. Cells were then
	separated by centrifugation at 15,000 x rpm for 5 min and dried in air. Dried cells were extracted
	with 10 μ L of 35%(v/v) formic acid. 1.5 μ L of extracted cell suspensions were mixed with 10 μ L of
	matrix solution. Then 1.5 μL of mixed solution was spotted onto the metal MALDI target and dried
	in air.

In order to ensure the repeatability of markers, samples were prepared from the re-cultured colonies and each type was measured nine times in total. The peak lists obtained from the mass spectra were subjected to multivariate analysis using the eMSTAT Solution software to differentiate *emm* types.



Fig. 3 Results of Multivariate Analysis of Group A Streptococcus (Score Plot)

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

Results and Discussion

Fig. 2 shows mass spectra of the group A streptococcus *emm1* type and other types. The mass spectrum patterns were similar and it was a challenge to differentiate them visually. However, by performing multivariate analysis (algorithm: PLS-DA), they were classified into two groups: the *emm1* type and the other types (Fig. 3).

Using the eMSTAT Solution software, it was possible to distinguish marker peaks detected in the MALDI spectra

which help to differentiate the *emm1* type from the other types. As a result of the search, we confirmed from the Peak Matrix table that the peak at m/z 10932 was detected with all 90 samples of the *emm1* type and, in contrast to this, was not detected with all samples of the other types (Fig. 4). This was confirmed in the mass spectra where we can see that the peak at m/z 10932 was detected only with the *emm1* type (Fig. 5).

Peak Ma	Peak Matrix 1519 neaks							
	m/z 🔺	ANOVA	emm1.0	emm12.0	emm28.0	emm89.0		
	10529.53	0.45215	0	1	0	0		
~	10580.12	0.022573	0	0	0	4		
~	10689.77	0.13804	5	1	9	2		
~	10697.97	1.1797E-16	64	80	55	84		
~	10706.51	0.32824	3	2	0	0		
~	10717.11	0.76438	2	1	2	3		
 Image: A second s	10725.56	0.27327	0	0	1	2		
~	10734.97	0.26564	0	2	0	4		
	10918.12	4.173E-74	0	88	90	89		
~	10931.66	8.8298E-56	90	0	0	0		
~	10951.27	0.45215	0	1	0			
~	10963.42	0.0097304	0	0		7		
~	10970.66	0.45215	1	0		0		
~	11000.27	0.0046591	6	0				
~	11007.57	0.45215	1	0				
~	11025.18	0.13935	0	3	0			

Fig. 4 Identification of Marker Peaks using the Peak Matrix Function



Fig. 5 Enlarged Mass Spectra of the Group A Streptococcus *emm1* Type and the Other Types

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

Excellence in Science

Next, we conducted a blind test of 379 clinically isolated strains using a marker peak of *m*/*z* 10932 as an indicator (Table 1). Among 379 strains, 97 strains were typed as the *emm1* type using a conventional genetic analysis, while 92 strains among these 97 strains (94.8 %) were typed as the *emm1* type using the MALDI-TOF MS technique, which

indicates a high positive agreement rate. In addition, 3 strains typed as non *emm1* type using the MALDI-TOF MS method were typed as *emm11* (n=1) and *emm28* (n=2) by the conventional method, which indicates a negative agreement rate of 98.9 % (Table 2).

emm1	97	
emm2	2	
emm3	4	
emm4	31	
emm6	2	
emm9	7	
emm11	11	
emm12	92	
emm28	59	
emm75	6	
emm77	1	
emm89	58	
emm112	3	
Other	6	
Total	379	

Table 1 Clinically Isolated Strains Used for Blind Test

Table 2 Results of Blind Test

<i>emm1</i> Type		Conventior (Genetic	Total	
		(+)	(-)	
Mass Spectrometry	(+)	92 (94.8 %)	3 (1.1 %)	95
	(-)	5 (5.2 %)	279 (98.9 %)	284
Total		97	282	379

Conclusions

Conventionally, the *emm* typing techniques need culturing, GAS isolation, *emm* gene amplification by PCR, and sequence analysis, and it takes three days before the result is obtained. On the other hand, using MALDI-TOF MS, the

result can be obtained within several tens of minutes after culturing. This is a new technique for typing the highly pathogenic *emm1* type in a short time, and its future development can be expected.

Typing of *emm1* Group A Hemolytic Streptococci Using MALDI-TOF MS

Reference

🕀 SHIMADZU Excellence in Science

> 1) Sakuma M, Morozumi M, Ubukata K, Iwata T, 2018. Discrimination of group A streptococcus emm1 type using MALDI-TOF MS.

Joint Meeting of the 67th Regional Meeting of the Japanese Association for Infectious Diseases (JAID) and the 65th Annual Meeting of Japanese Society of Chemotherapy (JSC) in the East Japan District

2) Grant under the category "Research on Emerging and Reemerging Infectious Diseases" (H22-013) from the Japanese Ministry of Health, Labour, and Welfare to K. Ubukata (http://www.mhlw.go.jp/english/)

The products and applications in this presentation are intended for Research Use Only(RUO). Not for use in diagnostic procedures. Not available in China.



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.